Vitrakvi (larotrectinib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation. 3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) v::NTRK1 Any solid tumor Larotrectinib
Sensitivity (+) v::NTRK2 Any solid tumor Larotrectinib
Sensitivity (+) v::NTRK3 Any solid tumor Larotrectinib